DEEPX Partners with Hyundai to Power Next-Gen AI Robots Ahead of IPO 
Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production 
Anthropic Nears $800 Billion Valuation as Investor Confidence Surges 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
Iran War Drives Asia's Plastic Crisis — and a Green Packaging Boom 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
Goldman Sachs FICC Revenue Falls 10% Amid Iran War Market Volatility 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
Qantas Raises Fuel Cost Forecast Amid Middle East Oil Crisis 
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
SK Hynix Shares Hit Record High Amid AI Memory Demand Surge 
Sam Altman Moves to Dismiss Punitive Damages in Sister's Sexual Abuse Lawsuit 
Hermès Q1 2026 Sales Miss Expectations Amid Iran War and China Slowdown 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
SHELTON, Conn., April 05, 2016 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced that Dr. Derek Chalmers, President and CEO, will present a company overview at the 15th Annual Needham Healthcare Conference on Tuesday, April 12, 2016, at 10:00 a.m. ET in New York City.
A live webcast of the presentation can be accessed under “Events and Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com. An archived webcast recording will be available on the Cara website for approximately 30 days.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates that target the body's peripheral nervous system and have demonstrated efficacy in patients with moderate-to-severe pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics.
INVESTOR CONTACT: Jesse Baumgartner Stern Investor Relations, Inc. 212-362-1200 [email protected] MEDIA CONTACT: Annie Starr 6 Degrees 973-415-8838 [email protected]
